Efficacy and Safety Ranking of HER2-Targeted TKIs in Advanced Breast Cancer: A Bayesian Network Meta-Analysis.

Li R, Huangfu R, Lan H, Zhang C, Hou K, Ping Y

Open source

DOI
10.1177/11795549261489524
Published
2026
Container
Clinical Medicine Insights. Oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1177/11795549261489524,
  title = {Efficacy and Safety Ranking of HER2-Targeted TKIs in Advanced Breast Cancer: A Bayesian Network Meta-Analysis.},
  author = {Li R and Huangfu R and Lan H and Zhang C and Hou K and Ping Y},
  year = {2026},
  journal = {Clinical Medicine Insights. Oncology},
  doi = {10.1177/11795549261489524},
  url = {https://doi.org/10.1177/11795549261489524}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety Ranking of HER2-Targeted TKIs in Advanced Breast Cancer: A Bayesian Network Meta-Analysis.
AU  - Li R
AU  - Huangfu R
AU  - Lan H
AU  - Zhang C
AU  - Hou K
AU  - Ping Y
PY  - 2026
JO  - Clinical Medicine Insights. Oncology
DO  - 10.1177/11795549261489524
UR  - https://doi.org/10.1177/11795549261489524
ER  - 

APA

R, L., R, H., H, L., C, Z., K, H., & Y, P. (2026). Efficacy and Safety Ranking of HER2-Targeted TKIs in Advanced Breast Cancer: A Bayesian Network Meta-Analysis.. Clinical Medicine Insights. Oncology. https://doi.org/10.1177/11795549261489524

Source records